Loading clinical trials...
Loading clinical trials...
A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft
Conditions
Interventions
Remodulin (treprostinil sodium) Injection
Locations
4
United States
Southern Illinois University School of Medicine
Springfield, Illinois, United States
University of Massachusetts Memorial Health Center
Worcester, Massachusetts, United States
Vascular Institute Albany Medical College
Albany, New York, United States
Oregon Health Sciences University
Portland, Oregon, United States
Start Date
March 1, 2003
Primary Completion Date
December 1, 2003
Completion Date
December 1, 2003
Last Updated
March 7, 2013
NCT06656988
NCT04927156
NCT06399809
NCT06399900
NCT03404180
NCT05009602
Lead Sponsor
United Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions